Cargando…

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China

This study was conducted to ascertain whether people in China would be willing to pay for an inactivated COVID-19 vaccine booster dose. An online survey estimating participants' willingness to pay (WTP) for a booster dose of COVID-19 vaccine was conducted in Taizhou, China. The participants rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tung, Tao-Hsin, Lin, Xiao-Qing, Chen, Yan, Zhang, Mei-Xian, Zhu, Jian-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746460/ https://www.ncbi.nlm.nih.gov/pubmed/35880816 http://dx.doi.org/10.1080/21645515.2022.2099210

Ejemplares similares

Willingness to pay for booster dose of COVID-19 vaccine among healthcare workers in Taizhou,China
por: Pan, Shuang-Jun, et al.
Publicado: (2022)

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
por: Shao, Hui, et al.
Publicado: (2023)

Why do parents willingness-to-pay to vaccinate their children against COVID-19? A real-world evidence in Taizhou, China
por: Tung, Tao-Hsin, et al.
Publicado: (2022)

Determinants of the willingness of medical staff to vaccinate their children with a booster dose of the COVID-19 vaccine in Taizhou, China
por: Huang, Li-Li, et al.
Publicado: (2022)

Relationship between COVID-19 vaccine hesitancy and willingness to pay for the booster dose of COVID-19 vaccine of oncology patients in Taizhou, China
por: An, Jia-Xiang, et al.
Publicado: (2023)

Parents’ willingness to pay for their children’s COVID-19 vaccine in Taiwan, China: A cross-sectional study
por: Huang, Chun-Lian, et al.
Publicado: (2023)

Willingness of Older Adults with Chronic Diseases to Receive a Booster Dose of Inactivated Coronavirus Disease 2019 Vaccine: A Cross-Sectional Study in Taizhou, China
por: Lin, Xiao-Qing, et al.
Publicado: (2022)

Post-vaccination adverse reactions, decision regret, and willingness to pay for the booster dose of COVID-19 vaccine among healthcare workers: A mediation analysis
por: Luo, Chengwen, et al.
Publicado: (2022)

The main decision-making competence for willingness-to-pay towards COVID-19 vaccination: a family-based study in Taizhou, China
por: Luo, Chengwen, et al.
Publicado: (2022)

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose
por: Chen, Liling, et al.
Publicado: (2023)

Association between health behaviours and the COVID-19 vaccination: risk compensation among healthcare workers in Taizhou, China
por: Sun, Liang-Xue, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China
por: Zhou, Hui Jun, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
por: Mungmunpuntipantip, Rujitika, et al.
Publicado: (2023)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Intentions of Patients with Hypertension to Receive a Booster Dose of the COVID-19 Vaccine: A Cross-Sectional Survey in Taizhou, China
por: Ying, Chen-Qian, et al.
Publicado: (2022)

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
por: Criscuolo, Elena, et al.
Publicado: (2021)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
por: Liang, Huang, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

COVID-19 vaccine booster dose hesitancy among key groups: A cross-sectional study
por: Huang, Min, et al.
Publicado: (2023)

Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
por: Xu, Hongqin, et al.
Publicado: (2023)

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
por: Sahay, Rima R., et al.
Publicado: (2022)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Neighborhood social cohesion is associated with the willingness toward the booster dose of COVID-19 vaccines among the Chinese older population
por: Qin, Chenyuan, et al.
Publicado: (2022)

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
por: Zhang, Zheng, et al.
Publicado: (2022)

Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
por: Mohapatra, Ranjan K., et al.
Publicado: (2022)

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection
por: Bingula, Rea, et al.
Publicado: (2023)

Adverse reactions to inactivated COVID-19 vaccination in patients with chronic liver disease: The effect of anxiety
por: Lv, Li, et al.
Publicado: (2022)

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
por: Sritipsukho, Paskorn, et al.
Publicado: (2023)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control study
por: Li, Fei-Ping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gn5r1u7qnt1ffn8kijo0ksjaro